{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T11:35:35.542549+00:00","company":{"ticker":"TLSI","cik":1826667,"company_name":"TriSalus Life Sciences, Inc."},"pagination":{"limit":100,"returned":77,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"MedTech Acquisition Sponsor LLC","detail":"credit_facility","count":3,"first_seen":"2022-12-02T23:59:59+00:00","last_seen":"2022-12-19T23:59:59+00:00","evidence_fact_ids":[190341,190342,193431]},{"display_name":"TriSalus Life Sciences, Inc.","detail":"merger","count":2,"first_seen":"2023-04-05T23:59:59+00:00","last_seen":"2023-04-05T23:59:59+00:00","evidence_fact_ids":[167013,167014]},{"display_name":"Lake Street Capital Markets, LLC","detail":"underwriting","count":1,"first_seen":"2026-02-20T23:59:59+00:00","last_seen":"2026-02-20T23:59:59+00:00","evidence_fact_ids":[31584]},{"display_name":"MTAC Merger Sub, Inc. and TriSalus Life Sciences, Inc.","detail":"merger","count":1,"first_seen":"2023-06-08T23:59:59+00:00","last_seen":"2023-06-08T23:59:59+00:00","evidence_fact_ids":[142044]},{"display_name":"MedTech Acquisition Corporation","detail":"merger","count":1,"first_seen":"2023-03-08T23:59:59+00:00","last_seen":"2023-03-08T23:59:59+00:00","evidence_fact_ids":[173225]},{"display_name":"MedTech Acquisition Corporation and MTAC Merger Sub, Inc.","detail":"merger","count":1,"first_seen":"2022-11-14T23:59:59+00:00","last_seen":"2022-11-14T23:59:59+00:00","evidence_fact_ids":[196932]},{"display_name":"OrbiMed Royalty & Credit Opportunities IV, LP","detail":"credit_facility","count":1,"first_seen":"2024-04-30T23:59:59+00:00","last_seen":"2024-04-30T23:59:59+00:00","evidence_fact_ids":[57553]},{"display_name":"YA II PN, Ltd.","detail":"equity_purchase","count":1,"first_seen":"2023-10-03T23:59:59+00:00","last_seen":"2023-10-03T23:59:59+00:00","evidence_fact_ids":[109195]}],"lender":[{"display_name":"MedTech Acquisition Sponsor LLC","detail":"loan","count":4,"first_seen":"2022-12-02T23:59:59+00:00","last_seen":"2023-06-15T23:59:59+00:00","evidence_fact_ids":[138685,190344,190345,193434]},{"display_name":"OrbiMed Royalty & Credit Opportunities IV, LP","detail":"credit_facility","count":2,"first_seen":"2024-04-30T23:59:59+00:00","last_seen":"2025-02-19T23:59:59+00:00","evidence_fact_ids":[57556,144503]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"257aa9939bcccc2ae201e50a56020691a13ef70c","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-14T20:03:27+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Advisory vote on compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"7,721,120","subject":null,"votes_abstain":"176,369","votes_against":"1,206,105","votes_for":"32,625,082","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-14 meeting.","evidence_excerpt":"The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers was approved by the stockholder vote: For Against Abstain Broker Non-Votes 32,625,082 1,206,105 176,369 7,721,120","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-035068","anchor_url":"https://secwatch.observer/filing/0001628280-26-035068#claim-257aa9939bcccc2ae201e50a56020691a13ef70c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"bceeeca28d067c41b22815aa1364d2db882c0623","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-14T20:03:27+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Advisory vote on frequency of future stockholder advisory votes on named executive officer compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"7,721,120","subject":"1 Year","votes_abstain":null,"votes_against":null,"votes_for":"12,656,430","votes_withheld":null},{"broker_non_votes":"7,721,120","subject":"2 Years","votes_abstain":null,"votes_against":null,"votes_for":"736,931","votes_withheld":null},{"broker_non_votes":"7,721,120","subject":"3 Years","votes_abstain":null,"votes_against":null,"votes_for":"20,348,386","votes_withheld":null},{"broker_non_votes":"7,721,120","subject":"Abstain","votes_abstain":null,"votes_against":null,"votes_for":"265,809","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Advisory vote on frequency of future stockholder advisory votes on named executive officer compensation at the 2026-05-14 meeting.","evidence_excerpt":"The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 12,656,430 736,931 20,348,386 265,809 7,721,120","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-035068","anchor_url":"https://secwatch.observer/filing/0001628280-26-035068#claim-bceeeca28d067c41b22815aa1364d2db882c0623","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3c22992d5bdb7dd8c67d0c1bcf26fd8d1f956dce","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-14T20:03:27+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Ratification of appointment of Grant Thornton, LLP as independent registered accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"601,624","votes_against":"28,667","votes_for":"41,098,385","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Ratification of appointment of Grant Thornton, LLP as independent registered accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.","evidence_excerpt":"The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote: For Against Abstain 41,098,385 28,667 601,624","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-035068","anchor_url":"https://secwatch.observer/filing/0001628280-26-035068#claim-3c22992d5bdb7dd8c67d0c1bcf26fd8d1f956dce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"eb598dfe2978147a1bd9fc9b768377fddd9575a9","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-14T20:03:27+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"7,721,120","subject":"Mary Szela","votes_abstain":null,"votes_against":null,"votes_for":"31,393,310","votes_withheld":"2,614,246"},{"broker_non_votes":"7,721,120","subject":"Gary Gordon","votes_abstain":null,"votes_against":null,"votes_for":"31,339,161","votes_withheld":"2,668,395"}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Election of Directors at the 2026-05-14 meeting.","evidence_excerpt":"The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows: Nominee For Withhold Broker Non-Votes Mary Szela 31,393,310 2,614,246 7,721,120 Gary Gordon 31,339,161 2,668,395 7,721,120","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-035068","anchor_url":"https://secwatch.observer/filing/0001628280-26-035068#claim-eb598dfe2978147a1bd9fc9b768377fddd9575a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm"},{"fact_type":"earnings_release","fact_key":"ce18857e14083ac6c9a78fef319b6150d8cce4a3","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-12T20:03:05+00:00","payload":{"eps_text":"$0.03","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.5 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":"$8.9 million"},"claim":"TriSalus Life Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $8.9 million, net income $1.5 million, EPS $0.03.","evidence_excerpt":"Revenue from the sale of the TriNav system, was $8.9 million for the three months ended March 31, 2026, a decrease of 2.9% compared to the same period in 2025.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001628280-26-034082","anchor_url":"https://secwatch.observer/filing/0001628280-26-034082#claim-ce18857e14083ac6c9a78fef319b6150d8cce4a3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/0001628280-26-034082-index.htm"},{"fact_type":"executive_change","fact_key":"eed195b25c","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-29","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Richard Marshall was appointed as Chief Medical Officer at TriSalus Life Sciences, Inc..","evidence_excerpt":"As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medical Officer of the Company, effective June 29, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-028425","anchor_url":"https://secwatch.observer/filing/0001628280-26-028425#claim-eed195b25c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026028425/0001628280-26-028425-index.htm"},{"fact_type":"executive_change","fact_key":"80772c891c","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2026-10-01","interim":false,"role":"Chief of Clinical Operations","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jodi Devlin departed as Chief of Clinical Operations at TriSalus Life Sciences, Inc..","evidence_excerpt":"On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-028425","anchor_url":"https://secwatch.observer/filing/0001628280-26-028425#claim-80772c891c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026028425/0001628280-26-028425-index.htm"},{"fact_type":"earnings_release","fact_key":"62be4f55f4b05d127560c79a5da7f201b86f7a9e","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-03-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"2026","report_date":"2026-03-05","result_type":"guidance_update","revenue_text":"$60 million to $62 million"},"claim":"TriSalus Life Sciences, Inc. reported 2026 results: revenue $60 million to $62 million. Guidance reaffirmed.","evidence_excerpt":"Reaffirms 2026 Revenue Guidance of $60-62 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-015155","anchor_url":"https://secwatch.observer/filing/0001628280-26-015155#claim-62be4f55f4b05d127560c79a5da7f201b86f7a9e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm"},{"fact_type":"earnings_release","fact_key":"73799a1b9a282b347cdbfd9ff20630d6d340c0c0","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-03-05T23:59:59+00:00","payload":{"eps_text":"$1.84","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$69.7 million","period_text":"the year ended December 31, 2025","report_date":"2026-03-05","result_type":"reported_results","revenue_text":"$45.2 million"},"claim":"TriSalus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $45.2 million, net income $69.7 million, EPS $1.84.","evidence_excerpt":"Revenue, all from sales of the TriNav system, was $45.2 million for the year ended December 31, 2025, an increase of 53% compared to the same period in 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-015155","anchor_url":"https://secwatch.observer/filing/0001628280-26-015155#claim-73799a1b9a282b347cdbfd9ff20630d6d340c0c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm"},{"fact_type":"earnings_release","fact_key":"d31db76134673b0861ff1252fbf50b2db69b6e51","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-03-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2025","report_date":"2026-03-05","result_type":"reported_results","revenue_text":"$13.2 million"},"claim":"TriSalus Life Sciences, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $13.2 million.","evidence_excerpt":"Generated $13.2 million in net sales, a 60% increase year-over-year","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-015155","anchor_url":"https://secwatch.observer/filing/0001628280-26-015155#claim-d31db76134673b0861ff1252fbf50b2db69b6e51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm"},{"fact_type":"material_agreement","fact_key":"8d3bb718842ea8132b8c24e6786efe87f03ad44b","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-02-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Lake Street Capital Markets, LLC","effective_date":"2026-02-19","item_codes_triggered":["1.01"],"value_text":null},"claim":"TriSalus Life Sciences, Inc. entered into Underwriting Agreement with Lake Street Capital Markets, LLC (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC (“LSCM”), as representative of the underwriters named therein (the “Underwriters”), relating to the public offering (the “Offering”) of 9,756,100 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price to the public of $4.10 per Share (the “Offering Price”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-007598","anchor_url":"https://secwatch.observer/filing/0001493152-26-007598#claim-8d3bb718842ea8132b8c24e6786efe87f03ad44b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/0001493152-26-007598-index.htm"},{"fact_type":"governance_change","fact_key":"cd9e66128ef576d5eed80f9591646f61d56fa2e4","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-07-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-24","item_codes_triggered":["5.03"],"summary_text":"Amended Certificate of Designations for Series A Convertible Preferred Stock to permit mandatory conversion upon closing of the exchange offer."},"claim":"TriSalus Life Sciences, Inc.: Amended Certificate of Designations for Series A Convertible Preferred Stock to permit mandatory conversion upon closing of the exchange offer (effective 2025-07-24).","evidence_excerpt":"on July 24, 2025, the Company filed the Preferred Stock Amendment with the Secretary of State of the State of Delaware. The Preferred Stock Amendment will permit the Company to require that all shares of Preferred Stock that are outstanding upon the closing of the Offer be converted into the number of shares of Common Stock equal to the quotient of (i) the sum of (a) the Liquidation Preference (as defined in the Certificate of Designations (defined below)) and (b) the Accrued Dividends (as defined in the Certificate of Designations) if not otherwise paid by the Company, that would have accrued through closing the Offer (the “Exchanged Value”), divided by the Conversion Price (as defined in the Certificate of Designations, as such term will be amended by the Preferred Stock Amendment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001826667-25-000103","anchor_url":"https://secwatch.observer/filing/0001826667-25-000103#claim-cd9e66128ef576d5eed80f9591646f61d56fa2e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000103/0001826667-25-000103-index.htm"},{"fact_type":"executive_change","fact_key":"c0f2ef0cc8","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-05-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-07-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"David Patience was appointed as Chief Financial Officer at TriSalus Life Sciences, Inc..","evidence_excerpt":"On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001826667-25-000071","anchor_url":"https://secwatch.observer/filing/0001826667-25-000071#claim-c0f2ef0cc8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/0001826667-25-000071-index.htm"},{"fact_type":"executive_change","fact_key":"a8e33fc47e","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-05-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-05-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"David Patience","successor_named":true},"claim":"James Young resigned as Chief Financial Officer at TriSalus Life Sciences, Inc..","evidence_excerpt":"Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001826667-25-000071","anchor_url":"https://secwatch.observer/filing/0001826667-25-000071#claim-a8e33fc47e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/0001826667-25-000071-index.htm"},{"fact_type":"executive_change","fact_key":"d00b670e6d","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-04-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-20","interim":false,"role":"Member of the Board, Audit Committee, and Compensation Committee","role_category":"director","successor_name":null,"successor_named":false},"claim":"George Kelly Martin resigned as Member of the Board, Audit Committee, and Compensation Committee at TriSalus Life Sciences, Inc..","evidence_excerpt":"On April 20, 2025, George Kelly Martin informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001826667-25-000036","anchor_url":"https://secwatch.observer/filing/0001826667-25-000036#claim-d00b670e6d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000036/0001826667-25-000036-index.htm"},{"fact_type":"executive_change","fact_key":"db1d75148f","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-04-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-16","interim":false,"role":"Member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Liselotte Hyveled resigned as Member of the Board at TriSalus Life Sciences, Inc..","evidence_excerpt":"On April 16, 2025, Liselotte Hyveled informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of her decision to resign from her position as a member of the Board, the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of the Board, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001826667-25-000033","anchor_url":"https://secwatch.observer/filing/0001826667-25-000033#claim-db1d75148f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000033/0001826667-25-000033-index.htm"},{"fact_type":"executive_change","fact_key":"5fdedb53b3","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2025-02-28","interim":false,"role":null,"role_category":"other","successor_name":null,"successor_named":false},"claim":"Sean Murphy departed as other at TriSalus Life Sciences, Inc..","evidence_excerpt":"On February 19, 2025, Sean Murphy notified TriSalus Life Sciences, Inc. (the “Company”) of his intent to step down as an officer and employee of the Company effective February 28, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001826667-25-000021","anchor_url":"https://secwatch.observer/filing/0001826667-25-000021#claim-5fdedb53b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000021/0001826667-25-000021-index.htm"},{"fact_type":"debt_financing","fact_key":"df4f33d048a2c57327ad831adc1e3438e39e2438","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-02-19T23:59:59+00:00","payload":{"counterparty":"OrbiMed Royalty & Credit Opportunities IV, LP","effective_date":"2025-02-18","event":"incurrence","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"April 30, 2029","principal_text":"$10 million"},"claim":"TriSalus Life Sciences, Inc. incurred term loan of $10 million with OrbiMed Royalty & Credit Opportunities IV, LP maturing April 30, 2029.","evidence_excerpt":"y ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, each other lender that may from time to time become a party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the lenders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001826667-25-000018","anchor_url":"https://secwatch.observer/filing/0001826667-25-000018#claim-df4f33d048a2c57327ad831adc1e3438e39e2438","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/0001826667-25-000018-index.htm"},{"fact_type":"executive_change","fact_key":"3239bdca78","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-01-31T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-29","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gary Gordon was appointed as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001826667-25-000011","anchor_url":"https://secwatch.observer/filing/0001826667-25-000011#claim-3239bdca78","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm"},{"fact_type":"executive_change","fact_key":"9c464e99f1","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-01-31T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-29","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William Valle was appointed as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001826667-25-000011","anchor_url":"https://secwatch.observer/filing/0001826667-25-000011#claim-9c464e99f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm"},{"fact_type":"executive_change","fact_key":"bd384f7f6a","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-01-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-01-06","interim":false,"role":"Chief Manufacturing, Strategy and Business Development Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sean Murphy was appointed as Chief Manufacturing, Strategy and Business Development Officer at TriSalus Life Sciences, Inc..","evidence_excerpt":"appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-002023","anchor_url":"https://secwatch.observer/filing/0001104659-25-002023#claim-bd384f7f6a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465925002023/0001104659-25-002023-index.htm"},{"fact_type":"executive_change","fact_key":"75f9db47e6","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-01-08T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-01-06","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"James Young changed role as Chief Financial Officer at TriSalus Life Sciences, Inc..","evidence_excerpt":"promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-002023","anchor_url":"https://secwatch.observer/filing/0001104659-25-002023#claim-75f9db47e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465925002023/0001104659-25-002023-index.htm"},{"fact_type":"executive_change","fact_key":"2a394e147d","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-11-01T23:59:59+00:00","payload":{"action":"no longer employed","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-10-29","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Steven Katz departed as Chief Medical Officer at TriSalus Life Sciences, Inc..","evidence_excerpt":"Effective October 29, 2024, Steven Katz, M.D., the Company’s Chief Medical Officer, is no longer employed by the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-113486","anchor_url":"https://secwatch.observer/filing/0001104659-24-113486#claim-2a394e147d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924113486/0001104659-24-113486-index.htm"},{"fact_type":"executive_change","fact_key":"5e33f81480","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-11-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Anil Singhal resigned as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On October 28, 2024, Anil Singhal, Ph.D., informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Compensation Committee of the Board and the Science and Technology Committee of the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-113486","anchor_url":"https://secwatch.observer/filing/0001104659-24-113486#claim-5e33f81480","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924113486/0001104659-24-113486-index.htm"},{"fact_type":"earnings_release","fact_key":"9ee02926d15c2949fda229f105bb3a3e1a8ef7ee","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$0.60","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$13.2 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":"$6.5 million"},"claim":"TriSalus Life Sciences, Inc. reported first quarter ended March 31, 2024 results: revenue $6.5 million, net income $13.2 million, EPS $0.60.","evidence_excerpt":"TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-061631","anchor_url":"https://secwatch.observer/filing/0001104659-24-061631#claim-9ee02926d15c2949fda229f105bb3a3e1a8ef7ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/0001104659-24-061631-index.htm"},{"fact_type":"debt_financing","fact_key":"177c2615bc98bab4e6ee1398dd8b4cbc5c641b6f","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"counterparty":"OrbiMed Royalty & Credit Opportunities IV, LP","effective_date":"2024-04-30","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"SOFR plus 8.50%","item_codes_triggered":["2.03"],"maturity_text":"April 30, 2029","principal_text":"$25 million"},"claim":"TriSalus Life Sciences, Inc. incurred credit facility of $25 million with OrbiMed Royalty & Credit Opportunities IV, LP at SOFR plus 8.50% maturing April 30, 2029.","evidence_excerpt":"On April 30, 2024, the Borrower borrowed the Initial Commitment Amount, resulting in gross proceeds to the Borrower of $25 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-055007","anchor_url":"https://secwatch.observer/filing/0001104659-24-055007#claim-177c2615bc98bab4e6ee1398dd8b4cbc5c641b6f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm"},{"fact_type":"material_agreement","fact_key":"98cd241ca1c50972951ff6e6ec31e02376478486","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Credit Agreement","agreement_type":"credit_facility","counterparty":"OrbiMed Royalty & Credit Opportunities IV, LP","effective_date":"2024-04-30","item_codes_triggered":["1.01"],"value_text":"Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $"},"claim":"TriSalus Life Sciences, Inc. entered into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP valued at Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $ (effective 2024-04-30).","evidence_excerpt":"On April 30, 2024 (the “ Closing Date ”), TriSalus Life Sciences, Inc., a Delaware corporation (the “ Company ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “ Lenders ”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “ Administrative Agent ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-055007","anchor_url":"https://secwatch.observer/filing/0001104659-24-055007#claim-98cd241ca1c50972951ff6e6ec31e02376478486","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm"},{"fact_type":"auditor_change","fact_key":"92842f09462334b7619de6d45f6e58b0ab46ac50","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Grant Thornton LLP","disagreement_text":null,"effective_date":"2024-04-12","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"TriSalus Life Sciences, Inc. engaged Grant Thornton LLP as its auditor.","evidence_excerpt":"On April 12, 2024, the Audit Committee approved the engagement of Grant Thornton LLP","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-047373","anchor_url":"https://secwatch.observer/filing/0001104659-24-047373#claim-92842f09462334b7619de6d45f6e58b0ab46ac50","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924047373/0001104659-24-047373-index.htm"},{"fact_type":"auditor_change","fact_key":"b1bc614e8ba9b751ad22f7aefae97cfe47a057a2","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"KPMG LLP","disagreement_text":null,"effective_date":"2024-04-12","item_codes_triggered":["4.01","4.02"],"non_reliance_signal":"none","successor_auditor_name":"Grant Thornton LLP"},"claim":"TriSalus Life Sciences, Inc. dismissed KPMG LLP as its auditor.","evidence_excerpt":"(a) Dismissal of Independent Registered Public Accounting Firm On April 12, 2024, the Audit Committee (the “Audit\nCommittee”) of the Board of Directors of TriSalus Life Sciences, Inc. (the “Company”) approved the dismissal of KPMG\nLLP (“KPMG”) as the Company’s independent registered public accounting firm. On April 12, 2024, KPMG was informed that\nthey were dismissed. KPMG’s audit reports on the Company’s\nconsolidated financial statements as of and for the years ended December 31, 2023 and 2022, did not contain any adverse opinion or a disclaimer","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-047373","anchor_url":"https://secwatch.observer/filing/0001104659-24-047373#claim-b1bc614e8ba9b751ad22f7aefae97cfe47a057a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924047373/0001104659-24-047373-index.htm"},{"fact_type":"earnings_release","fact_key":"d1e8e288c81dc90626e6b80b130c9a52b5ab2cbf","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2023","report_date":"2024-04-01","result_type":"reported_results","revenue_text":null},"claim":"TriSalus Life Sciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter and year ended December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-041538","anchor_url":"https://secwatch.observer/filing/0001104659-24-041538#claim-d1e8e288c81dc90626e6b80b130c9a52b5ab2cbf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/0001104659-24-041538-index.htm"},{"fact_type":"earnings_release","fact_key":"708537db5498f140fe7bb70df1df165955e1d76a","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year-ended December 31, 2023","report_date":"2024-03-11","result_type":"preliminary_results","revenue_text":"approximately $5.7 million for the fourth quarter of 2023"},"claim":"TriSalus Life Sciences, Inc. reported fiscal year-ended December 31, 2023 results: revenue approximately $5.7 million for the fourth quarter of 2023.","evidence_excerpt":"On March 11, 2024, TriSalus Life Sciences, Inc. (the “Company”) announced a preliminary unaudited financial update with respect to the Company’s fiscal year-ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-033157","anchor_url":"https://secwatch.observer/filing/0001104659-24-033157#claim-708537db5498f140fe7bb70df1df165955e1d76a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/0001104659-24-033157-index.htm"},{"fact_type":"earnings_release","fact_key":"d7e3c70147dc75091b85bf238eab6803cbeba3e4","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2023","report_date":"2023-12-31","result_type":"preliminary_results","revenue_text":null},"claim":"TriSalus Life Sciences, Inc. reported preliminary financial results for the year ended December 31, 2023.","evidence_excerpt":"TriSalus Life Sciences, Inc. (the “Company”) may use a slide presentation, in whole or in part, from time to time in presentation to investors, analysts and others that includes preliminary sales information for the year ended December 31, 2023, as well as a business and product update.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001104659-24-001818","anchor_url":"https://secwatch.observer/filing/0001104659-24-001818#claim-d7e3c70147dc75091b85bf238eab6803cbeba3e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924001818/0001104659-24-001818-index.htm"},{"fact_type":"earnings_release","fact_key":"54cb97ad4b4db11f2a1dbc3d2ebdbcc8dc46504f","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"eps_text":"Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023","period_text":"the three and nine month periods ended September 30, 2023","report_date":"2023-11-14","result_type":"reported_results","revenue_text":"$5.2 million"},"claim":"TriSalus Life Sciences, Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $5.2 million, net income $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023, EPS Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0.","evidence_excerpt":"Financial\nResults and Provides Business Update Completed merger with MedTech Acquisition Corporation\n(MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23,\nup 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data\ndemonstrating","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-117720","anchor_url":"https://secwatch.observer/filing/0001104659-23-117720#claim-54cb97ad4b4db11f2a1dbc3d2ebdbcc8dc46504f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/0001104659-23-117720-index.htm"},{"fact_type":"material_agreement","fact_key":"66a01333c46631a6d62da7af7a9524b396291ac0","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-10-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Standby Equity Purchase Agreement","agreement_type":"equity_purchase","counterparty":"YA II PN, Ltd. (Yorkville)","effective_date":"2023-10-02","item_codes_triggered":["1.01"],"value_text":"up to $30,000,000"},"claim":"TriSalus Life Sciences, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) valued at up to $30,000,000 (effective 2023-10-02).","evidence_excerpt":"On October 2, 2023, TriSalus Life Sciences, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-106087","anchor_url":"https://secwatch.observer/filing/0001104659-23-106087#claim-66a01333c46631a6d62da7af7a9524b396291ac0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923106087/0001104659-23-106087-index.htm"},{"fact_type":"governance_change","fact_key":"6edb564570e6f8ed66d347db17f5d296d3b68a35","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-16T23:59:59+00:00","payload":{"change_type":"shell_status","effective_date":"2023-08-10","item_codes_triggered":["5.06"],"summary_text":"MTAC ceased to be a shell company as a result of the Business Combination"},"claim":"TriSalus Life Sciences, Inc.: MTAC ceased to be a shell company as a result of the Business Combination (effective 2023-08-10).","evidence_excerpt":"MTAC ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-092586","anchor_url":"https://secwatch.observer/filing/0001104659-23-092586#claim-6edb564570e6f8ed66d347db17f5d296d3b68a35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm"},{"fact_type":"governance_change","fact_key":"008793caf12c726eca047512ffc97c349eecbe67","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-16T23:59:59+00:00","payload":{"change_type":"code_of_ethics","effective_date":"2023-08-10","item_codes_triggered":["5.05"],"summary_text":"Approved and adopted a new Code of Business Conduct and Ethics"},"claim":"TriSalus Life Sciences, Inc.: Approved and adopted a new Code of Business Conduct and Ethics (effective 2023-08-10).","evidence_excerpt":"on August 10, 2023, the New TriSalus Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-092586","anchor_url":"https://secwatch.observer/filing/0001104659-23-092586#claim-008793caf12c726eca047512ffc97c349eecbe67","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm"},{"fact_type":"governance_change","fact_key":"e85233074a7cf6b1f2db12dc1414a53d65f6ea4a","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-16T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-08-10","item_codes_triggered":["5.03"],"summary_text":"Adopted Amended and Restated Bylaws"},"claim":"TriSalus Life Sciences, Inc.: Adopted Amended and Restated Bylaws (effective 2023-08-10).","evidence_excerpt":"also adopted Amended and Restated Bylaws on August 10 , 2023 (the “Bylaws”), which replaced MTAC’s Amended and Restated Certificate of Incorporation and bylaws in effect as of such time","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-092586","anchor_url":"https://secwatch.observer/filing/0001104659-23-092586#claim-e85233074a7cf6b1f2db12dc1414a53d65f6ea4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm"},{"fact_type":"governance_change","fact_key":"45cdf6bc5705e4f935191b1a675d0a613acad284","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-08-10","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Incorporation with amendments proposed by Charter Proposal"},"claim":"TriSalus Life Sciences, Inc.: Filed Certificate of Incorporation with amendments proposed by Charter Proposal (effective 2023-08-10).","evidence_excerpt":"On August 10, 2023, the Company filed the Certificate of Incorporation with the Delaware Secretary of State","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-092586","anchor_url":"https://secwatch.observer/filing/0001104659-23-092586#claim-45cdf6bc5705e4f935191b1a675d0a613acad284","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm"},{"fact_type":"ma_transaction","fact_key":"4e0edd106a088595baa999e7fe09bc128dd37bca","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-16T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2023-08-10","consideration_text":null,"counterparty":null,"effective_date":"2023-08-10","item_codes_triggered":["5.01","2.01"]},"claim":"TriSalus Life Sciences, Inc. underwent a change of control (closed 2023-08-10).","evidence_excerpt":"As a result of the consummation of the Business Combination, a change of control of MTAC has occurred, and the stockholders of MTAC as of immediately prior to the Closing held 9.7% of the outstanding shares of New TriSalus Common Stock immediately following the Closing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-092586","anchor_url":"https://secwatch.observer/filing/0001104659-23-092586#claim-4e0edd106a088595baa999e7fe09bc128dd37bca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4116f6fee81f565e0ec6ecea072e9d43023739e3","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Director Nomination Proposal B","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"David J. Matlin","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"David L. Treadwell","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Christopher C. Dewey","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Director Nomination Proposal B at the 2023-08-08 meeting.","evidence_excerpt":"7B. Director Nomination Proposal B : i. David J. Matlin For Withheld 7,135,005 19,016","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-4116f6fee81f565e0ec6ecea072e9d43023739e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a5cc85da8756df765279c79efd1d2408bc272e78","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Director Nomination Proposal A","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"Anil Singhal","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Kerry Hicks","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Sean Murphy","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"David Matlin","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Mats Wahlström","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Andrew von Eschenbach","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Mary Szela","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"Arjun Desai","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"},{"broker_non_votes":null,"subject":"George Kelly Martin","votes_abstain":null,"votes_against":null,"votes_for":"7,135,005","votes_withheld":"19,016"}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Director Nomination Proposal A at the 2023-08-08 meeting.","evidence_excerpt":"7A. Director Nomination Proposal A : i. Anil Singhal For Withheld 7,135,005 19,016","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-a5cc85da8756df765279c79efd1d2408bc272e78","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2d31a9f4a41f9be9a220fbe5766cf5faf1537cbc","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"The Nasdaq Proposal","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,016","votes_for":"7,135,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved The Nasdaq Proposal at the 2023-08-08 meeting.","evidence_excerpt":"6. The Nasdaq Proposal : For Against Abstain 7,135,005 19,016 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-2d31a9f4a41f9be9a220fbe5766cf5faf1537cbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"846dfb29e7314362481647c233b6ec2abb45437e","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"The ESPP Proposal","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,021","votes_for":"7,135,000","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved The ESPP Proposal at the 2023-08-08 meeting.","evidence_excerpt":"5. The ESPP Proposal : For Against Abstain 7,135,000 19,021 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-846dfb29e7314362481647c233b6ec2abb45437e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"775a6d64442b712463357e08ac0503c9def22962","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"The Stock Plan Proposal","proposal_type":"equity_plan","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,021","votes_for":"7,135,000","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved The Stock Plan Proposal at the 2023-08-08 meeting.","evidence_excerpt":"4. The Stock Plan Proposal : For Against Abstain 7,135,000 19,021 0","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-775a6d64442b712463357e08ac0503c9def22962","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"81a4c43a4cba1d3209c6fd171cd4ab0a1e77857e","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Governance Proposal 3E","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,016","votes_for":"7,135,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3E at the 2023-08-08 meeting.","evidence_excerpt":"3E. Governance Proposal 3E : For Against Abstain 7,135,005 19,016 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-81a4c43a4cba1d3209c6fd171cd4ab0a1e77857e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3aca8baf295a208491d07a08751bcb2261c1c989","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Governance Proposal 3D","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,016","votes_for":"7,135,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3D at the 2023-08-08 meeting.","evidence_excerpt":"3D. Governance Proposal 3D : For Against Abstain 7,135,005 19,016 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-3aca8baf295a208491d07a08751bcb2261c1c989","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"590490201c57accfe5e6ec1f1d9383c7488bd4e4","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Governance Proposal 3C","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,016","votes_for":"7,135,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3C at the 2023-08-08 meeting.","evidence_excerpt":"3C. Governance Proposal 3C : For Against Abstain 7,135,005 19,016 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-590490201c57accfe5e6ec1f1d9383c7488bd4e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7538fd18f9ef66403dedbb78db9e53f0a1e2ac4b","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Governance Proposal 3B","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,016","votes_for":"7,135,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3B at the 2023-08-08 meeting.","evidence_excerpt":"3B. Governance Proposal 3B : For Against Abstain 7,135,005 19,016 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-7538fd18f9ef66403dedbb78db9e53f0a1e2ac4b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1fb6dbc196c8fc1cf9a2b0884230d92493617ed2","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"Governance Proposal 3A","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"20,016","votes_for":"7,134,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3A at the 2023-08-08 meeting.","evidence_excerpt":"3A. Governance Proposal 3A : For Against Abstain 7,134,005 20,016 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-1fb6dbc196c8fc1cf9a2b0884230d92493617ed2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"201da31ad3c883a825a6509fcc3e96f0360d5fb1","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"The Charter Approval Proposal","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"19,016","votes_for":"7,135,005","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved The Charter Approval Proposal at the 2023-08-08 meeting.","evidence_excerpt":"2. The Charter Approval Proposal : i. Class A Common Stock For Against Abstain 7,135,004 19,016 0 ii. Class B Common Stock For Against Abstain 1 0 0 iii. Total Common Stock For Against Abstain 7,135,005 19,016 0","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-201da31ad3c883a825a6509fcc3e96f0360d5fb1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6ea0ce5ec4ab28cbd8ba9922180efe8f156a9fa5","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-08","outcome":"passed","proposal_text":"The Business Combination Proposal","proposal_type":"merger_approval","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"2","votes_against":"19,016","votes_for":"7,135,003","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved The Business Combination Proposal at the 2023-08-08 meeting.","evidence_excerpt":"1. The Business Combination Proposal : For Against Abstain 7,135,003 19,016 2","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089074","anchor_url":"https://secwatch.observer/filing/0001104659-23-089074#claim-6ea0ce5ec4ab28cbd8ba9922180efe8f156a9fa5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"3a102db29b3d1354f8bc6b21dd69a2dca9e619b6","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-12-11","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$35 million market value of listed securities","notice_date":"2023-06-14","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(2)","reported_value":null,"rule_numbers":["5550(b)(2)"],"rules_cited_in_text":true},"claim":"TriSalus Life Sciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"June 14, 2023, MedTech Acquisition Corporation, a Delaware corporation (the “Company”), received a deficiency letter (the\n“Notice”) of non-compliance from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market\n(“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of\nListed Securities (“MVLS”) was below the $35 million minimum requirement for continued inclusion on The Nasdaq Capital Market\npursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The Notice has no\nimmediate effect on the Company’s Na","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-073335","anchor_url":"https://secwatch.observer/filing/0001104659-23-073335#claim-3a102db29b3d1354f8bc6b21dd69a2dca9e619b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923073335/0001104659-23-073335-index.htm"},{"fact_type":"governance_change","fact_key":"9461078a606fefb5d06e57b6e919010dd3265c72","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-06-12","item_codes_triggered":["5.03"],"summary_text":"Amended charter to extend business combination deadline to Sept 22, 2023, change authorized share increase vote standard, add Class B-to-Class A conversion right, and remove redemption limitation on net tangible assets."},"claim":"TriSalus Life Sciences, Inc.: Amended charter to extend business combination deadline to Sept 22, 2023, change authorized share increase vote standard, add Class B-to-Class A conversion right, and remove redemption limitation on net tangible assets (effective 2023-06-12).","evidence_excerpt":"On June 12, 2023, the Company held a special meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved (1) an amendment to the Company’s Amended and Restated Certificate of Incorporation, including the amendment thereto (the “Charter”), to extend the date by which the Company must consummate its Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board); (2) an amendment to the Charter such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law; (3) an amendment to the Charte","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-071602","anchor_url":"https://secwatch.observer/filing/0001104659-23-071602#claim-9461078a606fefb5d06e57b6e919010dd3265c72","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6ce35cdd951f61ba551750be5fa8deff806e196f","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less t","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"310","votes_against":"322","votes_for":"7,496,690","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less t.","evidence_excerpt":"Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less than $5,000,001 in order to allow the Company to redeem public shares irrespective of whether such redemption would exceed the redemption limitation. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 7,496,690 322 310","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-071602","anchor_url":"https://secwatch.observer/filing/0001104659-23-071602#claim-6ce35cdd951f61ba551750be5fa8deff806e196f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2daa09b0d11f1089b1951100cb2c67a73d7cddd6","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closi","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"572","votes_for":"7,496,750","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closi.","evidence_excerpt":"Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closing of a Business Combination at the option of the holder of the Founder Shares. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 7,496,750 572 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-071602","anchor_url":"https://secwatch.observer/filing/0001104659-23-071602#claim-2daa09b0d11f1089b1951100cb2c67a73d7cddd6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f8c8af188563259b1f2de6b7c9fc6d3671a80bdf","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may b","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"568","votes_for":"7,496,754","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may b.","evidence_excerpt":"Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN common stock 7,496,754 568 0 Class A common stock 1,246,754 568 0 Class B common stock 6,250,000 0 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-071602","anchor_url":"https://secwatch.observer/filing/0001104659-23-071602#claim-f8c8af188563259b1f2de6b7c9fc6d3671a80bdf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6038e038335c5f7ea67d0f12e1ec55f249e2caae","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-22","outcome":"passed","proposal_text":"Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board).","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"1,163,390","votes_for":"6,333,932","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). at the 2023-06-22 meeting.","evidence_excerpt":"The Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 6,333,932 1,163,390 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-071602","anchor_url":"https://secwatch.observer/filing/0001104659-23-071602#claim-6038e038335c5f7ea67d0f12e1ec55f249e2caae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm"},{"fact_type":"debt_financing","fact_key":"e7f890d82c6e549e22befb0358f2f118490ac6eb","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2023-06-15","event":"incurrence","instrument_type":"loan","interest_rate_text":"no interest","item_codes_triggered":["2.03"],"maturity_text":"upon the consummation of an initial business combination","principal_text":"up to $137,375.28"},"claim":"TriSalus Life Sciences, Inc. incurred loan of up to $137,375.28 with MedTech Acquisition Sponsor LLC at no interest maturing upon the consummation of an initial business combination.","evidence_excerpt":"ote”) in the aggregate principal amount of up to $137,375.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the\n“Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $137,375.28 to deposit into the Company’s","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-071602","anchor_url":"https://secwatch.observer/filing/0001104659-23-071602#claim-e7f890d82c6e549e22befb0358f2f118490ac6eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm"},{"fact_type":"material_agreement","fact_key":"d5e655f990d7bc452151d885f6e732fdb5d2a40a","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Subscription Agreements","agreement_type":"equity_purchase","counterparty":"certain investors","effective_date":"2023-06-07","item_codes_triggered":["1.01"],"value_text":"$17,855,020"},"claim":"TriSalus Life Sciences, Inc. entered into Subscription Agreements with certain investors valued at $17,855,020 (effective 2023-06-07).","evidence_excerpt":"On June 7, 2023, the Company and certain investors (collectively, the “ Subscribers ”) entered into subscription agreements (the “ Subscription Agreements ”), pursuant to, and subject to the conditions of which, the Subscribers have collectively subscribed for and agreed to purchase 1,785,502 shares of a to-be-authorized class of preferred stock, par value $0.0001 per share that will be designated as Series A Convertible Preferred Stock (the “ Series A Convertible Preferred Stock ”), at a purchase price of $10.00 per share, resulting in an aggregate purchase price of $17,855,020.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-069137","anchor_url":"https://secwatch.observer/filing/0001104659-23-069137#claim-d5e655f990d7bc452151d885f6e732fdb5d2a40a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923069137/0001104659-23-069137-index.htm"},{"fact_type":"material_agreement","fact_key":"3539a3f1d45f71c00e15b4b8f67d8c945b11e038","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment to the Agreement and Plan of Merger","agreement_type":"merger","counterparty":null,"effective_date":"2023-04-04","item_codes_triggered":["1.01"],"value_text":null},"claim":"TriSalus Life Sciences, Inc. amended First Amendment to the Agreement and Plan of Merger (effective 2023-04-04).","evidence_excerpt":"y that certain First Amendment to the Agreement and Plan of Merger, dated April 4, 2023 and that certain Second Amendment to the Agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-069137","anchor_url":"https://secwatch.observer/filing/0001104659-23-069137#claim-3539a3f1d45f71c00e15b4b8f67d8c945b11e038","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923069137/0001104659-23-069137-index.htm"},{"fact_type":"material_agreement","fact_key":"b47d71d6d12472ce1e2e67a2e154f6f1e50c9733","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"MTAC Merger Sub, Inc. and TriSalus Life Sciences, Inc.","effective_date":"2022-11-11","item_codes_triggered":["1.01"],"value_text":null},"claim":"TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MTAC Merger Sub, Inc. and TriSalus Life Sciences, Inc. (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger, as amended by that certain First Amendment to the Agreement and Plan of Merger, dated April 4, 2023 and that certain Second Amendment to the Agreement and Plan of Merger, dated May 13, 2023 (as amended, the “ Merger Agreement ”), with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-069137","anchor_url":"https://secwatch.observer/filing/0001104659-23-069137#claim-b47d71d6d12472ce1e2e67a2e154f6f1e50c9733","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923069137/0001104659-23-069137-index.htm"},{"fact_type":"material_agreement","fact_key":"366da117bb2b1238dc9d01deaaf2cfe0818c8976","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-04-05T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Agreement and Plan of Merger","agreement_type":"merger","counterparty":"TriSalus Life Sciences, Inc.","effective_date":"2023-04-04","item_codes_triggered":["1.01"],"value_text":"Amendment to provide for assumption by MTAC of TriSalus' restricted stock unit awards outstanding pr"},"claim":"TriSalus Life Sciences, Inc. amended Amendment to Agreement and Plan of Merger with TriSalus Life Sciences, Inc. valued at Amendment to provide for assumption by MTAC of TriSalus' restricted stock unit awards outstanding pr (effective 2023-04-04).","evidence_excerpt":"On April 4, 2023, MTAC, Merger Sub, and TriSalus amended the Merger Agreement (the “ Amendment ”) to, among other matters, provide for the assumption by MTAC of any restricted stock unit awards under TriSalus’ existing equity plan that are outstanding as of immediately prior to the closing of the Business Combination, which will be converted into restricted stock unit awards covering shares of Common Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-042182","anchor_url":"https://secwatch.observer/filing/0001104659-23-042182#claim-366da117bb2b1238dc9d01deaaf2cfe0818c8976","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/0001104659-23-042182-index.htm"},{"fact_type":"material_agreement","fact_key":"db15df2b64fc6927cc57953d2caf940bbe8fe4eb","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-04-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"TriSalus Life Sciences, Inc.","effective_date":"2022-11-11","item_codes_triggered":["1.01"],"value_text":"Merger of Merger Sub into TriSalus, TriSalus surviving as wholly owned subsidiary of MTAC, TriSalus"},"claim":"TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with TriSalus Life Sciences, Inc. valued at Merger of Merger Sub into TriSalus, TriSalus surviving as wholly owned subsidiary of MTAC, TriSalus (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock, par value $0.0001 per share (the “ Common Stock ” and the transactions contemplated by the Merger Agreement and the related ancillary agreements, the “ Business Combination ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-042182","anchor_url":"https://secwatch.observer/filing/0001104659-23-042182#claim-db15df2b64fc6927cc57953d2caf940bbe8fe4eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/0001104659-23-042182-index.htm"},{"fact_type":"material_agreement","fact_key":"9c37d4cc96e8deb5b8cffaac42ebbeee61263067","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-03-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"MedTech Acquisition Corporation","effective_date":"2022-11-11","item_codes_triggered":["1.01"],"value_text":"Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm"},"claim":"TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation valued at Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-030127","anchor_url":"https://secwatch.observer/filing/0001104659-23-030127#claim-9c37d4cc96e8deb5b8cffaac42ebbeee61263067","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/0001104659-23-030127-index.htm"},{"fact_type":"governance_change","fact_key":"9d0c7522701cd27f893a79f2272158142000feea","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2022-12-12","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to extend business combination deadline from December 22, 2022 to June 22, 2023"},"claim":"TriSalus Life Sciences, Inc.: Amended certificate of incorporation to extend business combination deadline from December 22, 2022 to June 22, 2023 (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, the Company held a special meeting in lieu of the 2022 annual meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Extension Amendment”) to extend the date by which the Company must consummate its initial business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The Company filed the Extension Amendment with the Secretary of State of the State of Delaware on December 12, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-9d0c7522701cd27f893a79f2272158142000feea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d265a87acc9e94124bbb54a787cbee67b9048deb","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Director Election Proposal - to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"Karim Karti","votes_abstain":"4,429,515","votes_against":null,"votes_for":"19,508,998","votes_withheld":null},{"broker_non_votes":null,"subject":"Martin Roche, MD","votes_abstain":"3,233,634","votes_against":null,"votes_for":"20,704,879","votes_withheld":null},{"broker_non_votes":null,"subject":"Thierry Thaure","votes_abstain":"3,233,890","votes_against":null,"votes_for":"20,704,623","votes_withheld":null},{"broker_non_votes":null,"subject":"Manuel Aguero","votes_abstain":"3,233,638","votes_against":null,"votes_for":"20,704,875","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Director Election Proposal - to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified..","evidence_excerpt":"(2) The Director Election Proposal — to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified. The following is a tabulation of the votes with respect to the election of directors, each of whom was elected by the Company’s stockholders: Name FOR ABSTAIN Karim Karti 19,508,998 4,429,515 Martin Roche, MD 20,704,879 3,233,634 Thierry Thaure 20,704,623 3,233,890 Manuel Aguero 20,704,875 3,233,638","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-d265a87acc9e94124bbb54a787cbee67b9048deb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0b39069fce01e2ecd622fa5df15c669a31b0cb9f","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-22","outcome":"passed","proposal_text":"Extension Amendment Proposal - to amend the Company's amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board).","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"32,602","votes_against":"2,962,183","votes_for":"20,943,728","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved Extension Amendment Proposal - to amend the Company's amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). at the 2022-12-22 meeting.","evidence_excerpt":"(1) The Extension Amendment Proposal — a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 20,943,728 2,962,183 32,602","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-0b39069fce01e2ecd622fa5df15c669a31b0cb9f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"debt_financing","fact_key":"81682bf3508a2b460e2f44727ad1df42dd745787","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2022-12-16","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its a","principal_text":"up to $1,000,000"},"claim":"TriSalus Life Sciences, Inc. incurred loan of up to $1,000,000 with MedTech Acquisition Sponsor LLC maturing the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its a.","evidence_excerpt":"on December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the “Working Capital Note”) to the Sponsor for working capital purposes, , which may be drawn down from time to time upon request by the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-81682bf3508a2b460e2f44727ad1df42dd745787","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"debt_financing","fact_key":"74b2de95528e8119ba0e0908297b020acf78c0cc","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2022-12-16","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"upon the date of the consummation of an initial business combination","principal_text":"up to $468,821.28"},"claim":"TriSalus Life Sciences, Inc. incurred loan of up to $468,821.28 with MedTech Acquisition Sponsor LLC maturing upon the date of the consummation of an initial business combination.","evidence_excerpt":"On December 16, 2022, the Company issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $468,821.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $468,821.28 (the “Extension Funds”) to deposit into the Company’s trust account (the “Trust Account”) for the shares of Class A common stock of the Company (the “Public Shares”) that were not redeemed in connection with the extension of the Company’s termination date from December 22, 2022 to June 22, 2023 or such earlier date as determined by the board of directors of the Company (the “Board”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-74b2de95528e8119ba0e0908297b020acf78c0cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"material_agreement","fact_key":"03757f268b41567bcb6b42c1cf24ce397ebb1ef2","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Working Capital Note","agreement_type":"credit_facility","counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2022-12-16","item_codes_triggered":["1.01"],"value_text":"up to $1,000,000"},"claim":"TriSalus Life Sciences, Inc. entered into Working Capital Note with MedTech Acquisition Sponsor LLC valued at up to $1,000,000 (effective 2022-12-16).","evidence_excerpt":"on December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the “Working Capital Note”) to the Sponsor for working capital purposes","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-03757f268b41567bcb6b42c1cf24ce397ebb1ef2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"material_agreement","fact_key":"34db97611100c23f83b8a2af87820a528b9a8550","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Extension Note","agreement_type":"credit_facility","counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2022-12-16","item_codes_triggered":["1.01"],"value_text":"$468,821.28"},"claim":"TriSalus Life Sciences, Inc. entered into Extension Note with MedTech Acquisition Sponsor LLC valued at $468,821.28 (effective 2022-12-16).","evidence_excerpt":"On December 16, 2022, the Company issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $468,821.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $468,821.28","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-127969","anchor_url":"https://secwatch.observer/filing/0001104659-22-127969#claim-34db97611100c23f83b8a2af87820a528b9a8550","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm"},{"fact_type":"shareholder_vote","fact_key":"eb86e65b9fa747131a71b46ca2b9d6af23a9769f","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"The Adjournment Proposal","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"56,835","votes_against":"4,839,932","votes_for":"18,357,148","votes_withheld":null}]},"claim":"TriSalus Life Sciences, Inc. shareholders approved The Adjournment Proposal at the 2022-12-07 meeting.","evidence_excerpt":"The sole proposal that was presented at the Special Meeting was the “The Adjournment Proposal”, which is a proposal allowing the MedTech board of directors to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to provide more time to seek approval of the Extension Amendment. The MedTech stockholders approved the Adjournment Proposal. The voting results were as follows: FOR AGAINST ABSTAIN 18,357,148 4,839,932 56,835","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-125257","anchor_url":"https://secwatch.observer/filing/0001104659-22-125257#claim-eb86e65b9fa747131a71b46ca2b9d6af23a9769f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922125257/0001104659-22-125257-index.htm"},{"fact_type":"debt_financing","fact_key":"1268f401ab2c6613097517b329251451de16d605","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-02T23:59:59+00:00","payload":{"counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2022-12-02","event":"amendment","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$544,000 and $400,000"},"claim":"TriSalus Life Sciences, Inc. amended loan of $544,000 and $400,000 with MedTech Acquisition Sponsor LLC.","evidence_excerpt":"disclosed, on December 30, 2021 and January 28, 2022, MedTech Acquisition Corporation (the “Company”) issued an\nunsecured promissory note in the principal amount of $544,000 and $400,000, respectively, to the Company’s sponsor, MedTech Acquisition\nSponsor LLC (the “Sponsor”), for working capital purposes. On\nDecember 2, 2022, the Company amended both","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-124148","anchor_url":"https://secwatch.observer/filing/0001104659-22-124148#claim-1268f401ab2c6613097517b329251451de16d605","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922124148/0001104659-22-124148-index.htm"},{"fact_type":"material_agreement","fact_key":"cff6f535f87a32f80316289dab833523ccd0be28","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-12-02T23:59:59+00:00","payload":{"action":"amendment","agreement_name":null,"agreement_type":"notes_offering","counterparty":"MedTech Acquisition Sponsor LLC","effective_date":"2022-12-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"TriSalus Life Sciences, Inc. amended a notes offering with MedTech Acquisition Sponsor LLC (effective 2022-12-02).","evidence_excerpt":"On December 2, 2022, the Company amended both promissory notes to clarify that the principal of the notes will not be payable if the Company fails to complete its initial business combination on or before the 24 month anniversary of its initial public offering or such extended date as provided in the Company's amended and restated certificate of incorporation, as amended from time to time.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-124148","anchor_url":"https://secwatch.observer/filing/0001104659-22-124148#claim-cff6f535f87a32f80316289dab833523ccd0be28","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922124148/0001104659-22-124148-index.htm"},{"fact_type":"material_agreement","fact_key":"8c4d9942187637d5d318fb74261c301a6bf613a1","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"MedTech Acquisition Corporation and MTAC Merger Sub, Inc.","effective_date":"2022-11-11","item_codes_triggered":["1.01"],"value_text":"$220,000,000"},"claim":"TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation and MTAC Merger Sub, Inc. valued at $220,000,000 (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (\" MTAC \"), entered into an Agreement and Plan of Merger (the \" Merger Agreement \") with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (\" Merger Sub \"), and TriSalus Life Sciences, Inc., a Delaware corporation (\" TriSalus \")","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-117666","anchor_url":"https://secwatch.observer/filing/0001104659-22-117666#claim-8c4d9942187637d5d318fb74261c301a6bf613a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/0001104659-22-117666-index.htm"},{"fact_type":"executive_change","fact_key":"5b6e052b11","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-03-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-03-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ivan Delevic resigned as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On March 4, 2022, Ivan Delevic notified MedTech Acquisition Corporation (“MedTech” or the “Company”) that he was resigning as a member of the Company’s Board of Directors and all other positions with the Company effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-031154","anchor_url":"https://secwatch.observer/filing/0001104659-22-031154#claim-5b6e052b11","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922031154/0001104659-22-031154-index.htm"},{"fact_type":"executive_change","fact_key":"d6b62651bd","cik":1826667,"ticker":"TLSI","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-02-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-02-19","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Maurice R. Ferré resigned as Director at TriSalus Life Sciences, Inc..","evidence_excerpt":"On February 19 2022, Maurice R. Ferré, MD notified MedTech Acquisition Corporation (“MedTech” or the “Company”) that he was resigning as a member of the Company’s Board of Directors and all other positions with the Company effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-026153","anchor_url":"https://secwatch.observer/filing/0001104659-22-026153#claim-d6b62651bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922026153/0001104659-22-026153-index.htm"}]}